These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23768748)

  • 21. Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage.
    Moreno A; Quereda C; Fortún J; Bárcena R; Pérez-Elías MJ; Casado JL; Rodríguez-Sagrado MA; Mateos ML; Blesa C; Moreno S
    AIDS; 2010 May; 24(8):1231-3. PubMed ID: 20421744
    [No Abstract]   [Full Text] [Related]  

  • 22. Which is the real efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in HCV infected patients with advanced fibrosis?
    Pellicelli AM; Romano M; Guarascio P; Vignally P
    J Hepatol; 2012 Sep; 57(3):704-5. PubMed ID: 22510262
    [No Abstract]   [Full Text] [Related]  

  • 23. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
    PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New therapies for hepatitis C virus infection.
    Bacon BR; Khalid O
    Mo Med; 2011; 108(4):255-9. PubMed ID: 21905441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C treatment: interferon free or interferon freer?
    Dusheiko G; Burney T
    Lancet; 2013 Jun; 381(9883):2063-5. PubMed ID: 23499437
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment for hepatitis C virus with pegylated interferon-α plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients.
    Masiá M; Robledano C; López N; Escolano C; Gutiérrez F
    J Antimicrob Chemother; 2011 Aug; 66(8):1861-8. PubMed ID: 21622971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of chronic hepatitis C in human immunodeficiency virus infected patients].
    Begovac J
    Acta Med Croatica; 2013 Oct; 67(4):351-9. PubMed ID: 24984336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Response to interferon therapy using mutations in the HCV-NS5A].
    Sakamoto M; Enomoto N
    Nihon Rinsho; 2011 May; 69 Suppl 4():234-8. PubMed ID: 22096925
    [No Abstract]   [Full Text] [Related]  

  • 29. Interferon-alpha in treatment of chronic hepatitis C in co-infected HIV-patients in combination with ribavirin and as a pre-load therapy in treatment-naive HIV-positive patients. 8th European Conference on Clinical Aspects and Treatment of HIV Infection (8th ECCATH), 29-31 October, Athens Greece.
    Tossing G
    Eur J Med Res; 2002 Jan; 7(1):44-6. PubMed ID: 11827840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents.
    Woodrell C; Weiss J; Branch A; Gardenier D; Krauskopf K; Kil N; Paredes H; Bichoupan K; Sigel K
    J Addict Med; 2015; 9(5):405-10. PubMed ID: 26291545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of PEG-interferon alfa-2a plus ribavirin as treatment for chronic HCV hepatitis in a child cured of ALL.
    Lo Nigro L; La Spina M; Mirabile E; Pisana P; Schilirò G; Guardo P
    Pediatr Blood Cancer; 2004 Aug; 43(2):185. PubMed ID: 15236293
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.
    Osinusi A; Bon D; Nelson A; Lee YJ; Poonia S; Shivakumar B; Cai SY; Wood B; Haagmans B; Lempicki R; Herrmann E; Sneller M; Polis M; Masur H; Kottilil S
    J Med Virol; 2014 Feb; 86(2):177-85. PubMed ID: 24166150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C.
    Kanda T; Yokosuka O
    JNMA J Nepal Med Assoc; 2011; 51(181):41-8. PubMed ID: 22335095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C viral kinetics as a determinant of stopping pegylated interferon and ribavirin in genotype 1 infection.
    Kim DY
    Gut Liver; 2014 Jul; 8(4):335-6. PubMed ID: 25071896
    [No Abstract]   [Full Text] [Related]  

  • 35. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure.
    Mandorfer M; Steiner S; Schwabl P; Payer BA; Aichelburg MC; Grabmeier-Pfistershammer K; Trauner M; Reiberger T; Peck-Radosavljevic M
    Wien Klin Wochenschr; 2016 Jun; 128(11-12):414-20. PubMed ID: 26659706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients.
    Hullegie SJ; Claassen MA; van den Berk GE; van der Meer JT; Posthouwer D; Lauw FN; Leyten EM; Koopmans PP; Richter C; van Eeden A; Bierman WF; Newsum AM; Arends JE; Rijnders BJ
    J Hepatol; 2016 Apr; 64(4):807-12. PubMed ID: 26689767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
    Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M;
    Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
    J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
    Lo AO; Chan HL; Wong VW; Wong GL
    J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.